医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Approval for Listing of Shares of Solasia on the Tokyo Stock Exchange Mothers

2017年02月21日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President and CEO: Yoshihiro Arai, hereinafter “Solasia”) an oncology specialized pharmaceutical company developing oncology products for Asian commercial markets, announced today the approval for listing of shares on the Tokyo Stock Exchange (TSE) Mothers.

The scheduled date of the listing of the shares is Friday March 24, 2017, on or after which date the shares will be available for trading on the TSE Mothers.

The proceeds from this offering will be directed primarily to development and commercialization activities, and to execute on the company’s mission of providing “Better medicine for a brighter tomorrow”.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170220005733/en/

CONTACT

for Solasia Pharma K.K.
Rie Toyoda, +81-3-6721-8317
Investors
Relations

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • フェリング・ファーマシューティカルズ:夜中のトイレ起きは質の悪い睡眠の最大の原因であると専門家らが世界睡眠デーで指摘
  • GI Dynamics to Release 2016 Annual Report and Host Webcast for Year Ending 31 December 2016
  • Primary Health Care Limited (Primary) Signs Deal to Deploy Intelerad Medical Imaging Software Platform
  • Watts Sponsors Water Filtration Tower at Elementary School in the Philippines on World Water Day
  • Alexion Submits Application in Japan for Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)